Qiagen N.v. · NYSE:QGEN
Qiagen — Barclays Global Healthcare Conference 2026
62 slides from Qiagen's conference presentation, March 2026
Slide 1: Committed to solid profitable growth
Committed to solid profitable growth Investor Introduction March 2026 Presentation Titel
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 3: The value of biology has never been stronger
The value of biology has never been stronger Crucial to Improving Direct impact advancing healthcare on your science for all lives Investor Introduction Presentation Titel 3
Slide 4: QIAGEN solutions are used worldwide by researchers
QIAGEN solutions are used worldwide by researchers - from young scientists to Nobel laureates - and clinical labs Investor Introduction Presentation Titel 4
Slide 5: QIAGEN at a glance
QIAGEN at a glance Highly recurring revenues ~5,700 ~90% Consumables and related employees known as QIAGENers revenues ~10% Instruments >500,000 customers worldwide A global company with scale ~52% Balanced customer markets Americas $2.09 billion sales(1) Sales1 ~34% EMEA R&D continuum ~14% Life Mol
Slide 6: QIAGEN more focused and stronger than ever
QIAGEN more focused and Growth and value stronger than ever ~4-6% CAGR ~$13-14 bn ~$11 bn addressable Life Molecular addressable market QIAGEN market (2028) Sciences Diagnostics customers (2024) ~50% ~50% QIAGEN product Sample technologies Balanced global presence 2025 net sales (%) groups 52 34 14
Slide 7: Leading from the first step in lab workflows
Leading from the first step in lab workflows Samples Sample preparation Detection Insights PCR QIAcuity dPCR #2 Any Genomics / NGS Sample #1 biological technologies QIAGEN Digital Insights #1 sample Diagnostic solutions QuantiFERON #1 QIAstat-Dx #2 Life Sciences Customers Molecular Diagnostics Custo
Slide 8: Strategy: Committed to solid profitable growth
Strategy: Committed to solid profitable growth Our 2028 On track targets Ongoing focus on growth pillars to At least $2 bn sustain profitable growth net sales CER from pillars in 2028 On track ~7% Set to exceed Net sales CER CAGR (2024-28) Drive efficiency and digitization to At least 250 bps fuel g
Slide 9: Focusing on attractive opportunities in molecular testing
Focusing on attractive opportunities in molecular testing Product PCR / Nucleic acid Sample technologies Diagnostic solutions NGS / Genomics groups amplification 2025 sales $661 mn $803 mn $309 mn $242 mn Accelerate investments for growth Build on proven leadership QIAcuity #2 QIAstat-Dx #2 QIAGEN #
Slide 10: QIAcuity dPCR
QIAcuity dPCR Quantitative PCR QIAcuity dPCR Next-generation (qPCR) Enabling novel applications sequencing (NGS) e.g., Cell and Gene Therapy e.g., liquid biopsy Lower sensitivity High sensitivity and precision In-depth insights and precision More accurate than qPCR and high precision dPCR – Capturin
Slide 11: Instruments tailored to varying customer segments
Instruments tailored to varying customer segments Key achievements Scalable systems Low- to high- throughput capabilities QIAcuity One QIAcuity Four QIAcuity Eight QIAcuity-Dx >3,200 cumulative placements Academia since 2020 launch Overcoming entry barrier vs. qPCR Ease of use Fully integrated Trans
Slide 12: Significant investments into QIAcuity dPCR
Significant investments into QIAcuity dPCR ≥$250 mn QIAcuity net sales CER target (2028) Target Extend Accelerate commercialization new applications into clinical use >3x increase Launch new assays QIAcuity-Dx of sales specialists for market for gene expression and Cell and Gene enabling MRD and mon
Slide 13: QIAstat-Dx
QIAstat-Dx Use case: 3-year-old with severe but unspecific GI symptoms Traditional testing Syndromic testing Slow diagnosis and treatment Fast diagnosis enabling better decisions can lead to complexities treatment decisions Identifying unknown diseases at speed Day 1 Day 1 One test within and ease o
Slide 14: QIAstat-Dx offers differentiated features
QIAstat-Dx offers differentiated features Key achievements Strong product capabilities Key differentiators Specification QIAstat-Dx Competition Workflow Additional >5,200 cumulative placements efficiency pathogens since launch Hands-on time ~1 min >5 min and safety on panels for for broader robust r
Slide 15: Expanding global presence and differentiated menu
Expanding global presence and differentiated menu ≥$200 mn QIAstat-Dx net sales CER target (2028) Grow installed Small hospitals Medium hospitals Large hospital networks customer Public health labs Regional reference labs National reference labs base Low-throughput High-throughput customers customer
Slide 16: QIAGEN Digital Insights unlocking the power of genomics
QIAGEN Digital QIAGEN unlocking the power of genomics Insights Development Genomic data In 2003, the first Today, any human human genome took genome can be read in 13 years 5 hours Sequencing Powerful analytics costs $100 / to understand >$1 bn / genome sequencing run 2000 2010 2020 2030 genomics Th
Slide 17: Top bioinformatics for research to clinical customers
Top bioinformatics for research to clinical customers Key achievements Addressing large customer base Delivering QDI software solutions for NGS workflow #1 Research – in bioinformatics software for research and clinical Scientific discovery Pharma / Biotech Academia Government research Sample prep L
Slide 18: Case study: Research Advancing drug development
Case study: Research Advancing drug development Pharma challenge QDI pivotal to drug discovery Over 50,000 scientific publications cite our software Key to understanding disease pathways, targets and measure changes 25 of the Top 25 Pharma companies use QDI Significant number of failures without the
Slide 19: Case study: Clinical Enhancing patient outcomes
Case study: Clinical Enhancing patient outcomes Patient situation QDI-enhanced patient outcome Mutation identification and recommendation by QDI Profile Male (early 70s) Targeted therapy leading to life-saving disease remission Diagnosis QIAGEN Clinical Leukemia linked to rare gene mutation Insights
Slide 20: Genoox: The AI-powered software platform
Genoox: The AI-powered software platform Speed Accuracy Confidence Optimized for clinical turnaround AI workflows augmented by scientists Proven across >5.5 million reports Continuous feedback through users AI outputs validated by expert review Gold-standard knowledge databases How we win How we win
Slide 21: Focus on SaaS subscription model and AI
Focus on "SaaS" subscription model and AI to expand market leadership 2028 goals Coming in 2026 Deepen global commercial reach and +40% 4 new AI-enhanced SaaS sales SaaS transition for sustainable growth specialists commercial offerings Agentic AI interface for >14 NGS data analysis Invest in new AI
Slide 22: Investing to extend market leadership
Investing to extend market leadership ≥$200 mn QDI net sales CER target (2028) Extend leadership in curated Deepen global Invest in new AI and other knowledge commercial reach technologies Expand QIAGEN knowledge base into Adopt SaaS go-to-market Continue advancing software spatial, proteomics and m
Slide 23: Sample technologies: #1 in the first step of every molecular workflow
Sample technologies: #1 in the first step of every molecular workflow Laboratory workflow Differentiated solutions for modular, Valuable Biological Sample PCR integrated workflows molecular sample technologies Fast time to result, scalability insights Critical first step and ease of use dPCR in mole
Slide 24: QIAGEN leading the way in sample preparation
QIAGEN leading the way in sample preparation Comprehensive consumables ANY >350 ANY Key achievements biological sample different sample kits DNA / RNA portfolio e.g., tissue, cells, blood, for manual and target analytes >120 mn including variations QIAGEN preparations serum, wastewater automated pro
Slide 25: Scaling automation for the future
Scaling automation for the future Key initiatives Manual QIAcube Connect EZ2 Connect QIAcube HT QIAsymphony Low-throughput Mid-throughput High-throughput Expand state- of-the-art portfolio NEW QIAmini QIAsymphony QIAsprint Update Connect Connect automation Launch 2026 Launched in 2025 Launched in 20
Slide 26: On the offense expanding our top automation portfolio
On the offense expanding our top automation portfolio ≥$750 mn On On Sample technologies track track net sales CER target QIAsprint Connect QIAsymphony Connect QIAmini (2028) Launch 2026 Launched in February 2026 Full IVDR launch mid-2026 Launch Fall 2026 • High-throughput automation • Fully automat
Slide 27: Extending our Sample tech leadership with single-cell solutions
Extending our Sample tech leadership with single-cell solutions Driving the next wave of growth ~$2.1 bn Expanding Expected single-cell market by 2029 Key applications in oncology, immunology and neurology ~10% CAGR AI-driven 2024 - 2029 Generates data fueling AI-powered drug discovery 3,000+ Adopte
Slide 28: Parse: Breaking single-cell limits
Parse: Breaking single-cell limits Scalable High quality AI ready Designed for next-gen biology Validated for consistent performance Built for translational reality >1,000x higher single-cell scale Data quality determines value at AI models need biologically diverse reported over the last 10 years s
Slide 29: QuantiFERON Tuberculosis: A highly contagious and lethal bacterial infection
QuantiFERON Tuberculosis: A highly contagious and lethal bacterial infection 1 in 4 Broad health risk Global relevance people have a latent TB bacterial infection High risk of ssion to active ogre TB pr 1 in 10 EMEA of these people will develop an Immunocompromised ~10 mn active TB bacterial infecti
Slide 30: Best-positioned test for latent TB detection
Best-positioned test for latent TB detection QuantiFERON Tuberculin Key achievements Advantages over Specification blood test skin test skin test Customizable automated workflow High accuracy and specificity $503 mn 2025 net sales (+110% vs. 2019) Only one patient visit Electronic results Quality-as
Slide 31: Driving skin test conversion with unrivaled automation
Driving skin test conversion with unrivaled automation ≥$600 mn QuantiFERON Leading automation advantage net sales CER target (2028) Automated Automated Increase liquid handling assay and result Partnership with customer base Diasorin to expand into Lyme disease (EU and U.S.) Large potential in skin
Slide 32: Initiatives to fuel growth investments
Initiatives to fuel growth investments and achieve ≥31% adjusted operating income margin in 2028 Operational excellence Digitization Positioning QIAGEN for stronger profitable growth Accelerating growth and efficiency across QIAGEN Organizational design Portfolio streamlining >3.5 million ~30 commer
Slide 33: Executing our strategy with empowered QIAGENers
Executing our strategy with empowered QIAGENers ~5,700 QIAGENers Expand our culture of empowerment ~50% new top leaders since 2020 Foster accountability and decentralized decision-making ~15% with QIAGEN for >15 years Investor Introduction 33
Slide 34: Embracing ESG for all stakeholders
Embracing ESG for all stakeholders Net zero Top ESG ratings Environmental responsibility carbon emission target (2050) Investing in people 37% female leadership (2025) Serving society 75.7 Service NPS-T score exceeding goal of 64.5 (2025) Business with integrity ~8,000 compliance trainings completed
Slide 35: Q4 and FY 2025 results
Q4 and FY 2025 results Continuously delivering solid profitable growth February 4, 2026
Slide 36: Q4 and FY 2025: Solid results with adjusted EPS exceeding outlook
Q4 and FY 2025: Solid results with adjusted EPS exceeding outlook Growth 2025 FY: $2.090 bn Q4 growth ahead of outlook and FY 2025 growth at high end of outlook ($2.069 bn CER) • Q4: +1% CER growth above outlook of ~+0% CER Net sales • FY: +5% CER growth at high end of outlook of ~+4-5% CER Q4: $540
Slide 37: Q4 2025: Sales performance and key developments
Q4 2025: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) +1% Sample • +5% CER growth driven by automated consumables CER(1) technologies • Parse acquisition adds highly scalable single-cell kits 521 540 • +5% CER growth on gains in U.S a
Slide 38: Q4 2025: Portfolio developments
Q4 2025: Portfolio developments Sample technologies: QIAstat-Dx: Parse: Breaking single-cell limits Expanding syndromic testing access Expanding Sample technologies into scalable Submission of blood culture identification single-cell workflows (BCID) panels • Acquisition of Parse, adding single-cell
Slide 39: Q4 2025: Advancing automation of QuantiFERON test
Q4 2025: Advancing automation of QuantiFERON test Why does QuantiFERON win? UNIVERSAL AUTOMATION WORKFLOW customizable to labs of all sizes with fast time to result WELL ESTABLISHED AND DIFFERENTIATED QuantiFERON testing infrastructure Launch of next-generation LIAISON NEW QuantiFERON-TB Gold Plus I
Slide 40: FY 2025: Sales performance and key developments
FY 2025: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) • QIAsymphony Connect launched, QIAsprint Connect and +5% Sample QIAmini on track for launch in 2026 CER(1) technologies • Parse expands reach into clinical and translational workf
Slide 41: 2025: Adjusted EPS growth supported by operating profitability
2025: Adjusted EPS growth supported by operating profitability Adj. operating income margin Adj. diluted EPS ahead of Q4 and FY 2025 outlook ~+2 ppt 29.5% ~-1 ppt ~+1.6 ppt Q4 2025: $0.62 28.7% ~-0.8 ppt Adj. EPS(1) ~-0.5 ppt $0.62 CER vs. ~$0.60 CER outlook ~-0.4 ppt ~-0.1 ppt FY 2025: $2.38 Adj. E
Slide 42: Q4 and FY 2025: Continued solid operating cash flow generation
Q4 and FY 2025: Continued solid operating cash flow generation Cash flow(1) Debt maturity overview (3) 770 (in $ millions) 20 In $ millions Q4 2025 Operating cash flow 188 Purchases of PP&E(2) -71 500 Free cash flow 117 750 151 165 In $ millions FY 2025 82 125 Operating cash flow 654 26 Purchases of
Slide 43: 2026: Preparing for future growth across pillars
2026: Preparing for future growth across pillars Sample tech QuantiFERON QIAcuity QIAstat-Dx QDI Leveraging automation in Advancing workflow and Driving growth and preparing Broadening syndromic Capitalizing on top market high-value areas customer retention new generation testing panels position wit
Slide 44: 2026: Leveraging a solid portfolio to drive growth
2026: Leveraging a solid portfolio to drive growth Sample tech QuantiFERON QIAcuity QIAstat-Dx QDI Growth pillars total sales (CER) $1.49 bn 2025 target achieved $653 mn $501 mn $87 mn $136 mn $112 mn CER sales 8% CER growth 2025 $1.49 bn ~$650 mn ~$500 mn ~$105 mn ~$130 mn ~$105 mn CER targets ~$1.
Slide 45: Adj. operating income margin expansion
Adj. operating income margin expansion ~+2 ppt 29.5% ~-1 ppt ~+1.6 ppt ~29.5% 28.7% ~-0.8 ppt ~-0.5 ppt ~-0.4 ppt ~-0.1 ppt FY 2024 Tariff Currency Efficiency FY 2025 Parse Currency Tariff Efficiency FY 2026 headwinds movements program acquisition movements(1) headwinds program (incremental) Continu
Slide 46: FY 2026 growth trajectory driven by accelerators in H2
FY 2026 growth trajectory driven by accelerators in H2 7% ~+0.5 ppt ~+7-8% ~+0.5 ppt 6% ~+2 ppt 5% 5,0 ~+2 ppt ~+2-3% 1% Q1 2025 Q2 2025 Q3 2025 Q4 2025 H1 2026 End of New Sample QuantiFERON Better U.S. H2 2026 CER NeuMoDx, tech systems, Life Science CER growth Dialunox new product environment growt
Slide 47: 2026 outlook: Positioned for growth
2026 outlook: Positioned for growth Drive solid sales growth through pillars Our 2028 targets Launch new platforms and expand menu to drive recurring revenues ~7% Net sales CER CAGR Leverage portfolio in high-value areas (2024-28) Increase focus on applications offering dynamic growth ≥31% Deliver v
Slide 48: Transition in QIAGEN Supervisory Board
Transition in QIAGEN Supervisory Board Mark Stevenson QIAGEN Supervisory Board members – Appointed to Supervisory Board in 2026 Extensive industry and international experience • New independent member of the Supervisory Board in January 2026 • Brings extensive operational leadership and Stephen H. R
Slide 49: Q1 and FY 2026: Outlook and assumptions
Q1 and FY 2026: Outlook and assumptions (As of February 4, 2026) Q1 2026 outlook FY 2026 outlook Net sales ≥+1% CER ≥+5% CER Anticipated currency impact(1) Positive impact of ~+2-3 ppt Positive impact of ~+1 ppt Adjusted diluted EPS(2) ≥$0.54 CER ≥$2.50 CER Anticipated currency impact(1) Neutral Neu
Slide 50: Appendix
QIAGEN Appendix
Slide 51: Q4 2025: Consolidated Statements of Income
Q4 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Three months ended Three months ended December 31, 2025 December 31, 2024 Net sales 540,420 521,202 Cost of sales: Cost of sales 200,240 174,401 Acquisition-related intangible amortization 14,911 13,511 Total
Slide 52: FY 2025: Consolidated Statements of Income
FY 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Twelve months ended Twelve months ended December 31, 2025 December 31, 2024 Net sales 2,089,999 1,978,214 Cost of sales: Cost of sales 735,268 952,323 Acquisition-related intangible amortization 55,236 58,541
Slide 53: 2025: Quarterly sales by product group
2025: Quarterly sales by product group Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 150 -3% -1% 166 2% 0% 170 5% 3% 175 8% 5% 661 3% 2% Diagnostic s
Slide 54: 2025: Quarterly sales by product type and region
2025: Quarterly sales by product type and region Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 435 6% 8% 476 8% 6% 481 7% 6% 484 5%
Slide 55: Q4 and FY 2025: Reconciliation to adjusted results
Q4 and FY 2025: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pre-tax Income Tax Net Diluted sales profit income income tax rate income EPS* Fourth quarter 2025 Reported results 540.4 325.3 99.5 109.2 (1.4) 1 % 107.8 0.49 Adjustments Business integrat
Slide 56: Q4 and FY 2025: Footnotes for reconciliation to adjusted results
Q4 and FY 2025: Footnotes for reconciliation to adjusted results (unaudited) a. Results include costs for acquisition projects, including the acquisition of GNX Data Systems Ltd. (doing business as Genoox) completed in May 2025 and Parse Biosciences completed in December 2025. It also includes costs
Slide 57: 2025: Quarterly income statement summary
2025: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Net sales 483.5 533.5 532.6 540.4 2,090.0 Net sales (CER) 491.2 525.8 524.8 527.4 2,069.0 Gross profit 308.7 334.3 331.3 325.3 1299.5 Gross profit margin 63
Slide 58: Consolidated Balance Sheets
Consolidated Balance Sheets (unaudited) December 31, December 31, December 31, December 31, (In $ thousands, except par value) 2025 2024 (In $ thousands, except par value) 2025 2024 (revised) (revised) Assets Liabilities and Equity Cash and cash equivalents 839,005 663,555 Current portion of long-te
Slide 59: Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows (unaudited) Twelve months ended December 31, December 31, Twelve months ended December 31, December 31, (In $ thousands) 2025 2024 (In $ thousands) 2025 2024 Cash flows from operating activities: Cash flows from financing activities: Net income 424,880 83,591 Pr
Slide 60: Q4 and FY 2025: Currency impact
Q4 and FY 2025: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q4 2025 U.S. dollar 293.3 293.4 56% 0.1 Euro 114.1 104.6 20% -9.5 British pound 18.9 18.3 3% -0.6 Japanese yen 11.1 11.2 2% 0.1 Other currencies 103.0 99.9
Slide 61: Employees as of December 31, 2025
Employees as of December 31, 2025 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q4 2025 Q3 2025 Change Production 294 1,106 142 1,542 1,530 1% R&D 170 750 55 975 992 -2% Sales 584 833 702 2,119 2,126 0% Marketing 76 174 71 321 319 1% Administration 86 455 156 697 693
Slide 62: Your contacts
Your contacts Daniel Wendorff Calendar Vice President E-mail: Head of Investor Relations Q1 2026 results May 2026 ir@qiagen.com Phone: +49 2103 29 11322 Internet: Annual General Meeting June 2026 E-mail: daniel.wendorff@qiagen.com corporate.QIAGEN.com Q2 2026 results August 2026 Dr. Domenica Martora